About-cancer/treatment/clinical-trials/disease/melanoma/treatment

Daaweynta Tijaabooyinka Daaweynta ee Melanoma

Tijaabooyinka caafimaad waa daraasado cilmi baaris ah oo dadka ku lug leh. Tijaabooyinka caafimaad ee liiskan waxaa loogu talagalay daaweynta melanoma. Dhammaan tijaabooyinka ku jira liiska waxaa taageera NCI.

Macluumaadka aasaasiga ah ee NCI ee ku saabsan tijaabooyinka bukaan socodka wuxuu sharxayaa noocyada iyo wejiyada tijaabooyinka iyo sida loo fuliyo. Tijaabooyinka caafimaad waxay eegaan habab cusub oo looga hortago, lagu ogaado, ama lagu daweeyo cudur. Waxaa laga yaabaa inaad rabto inaad ka fikirto kaqeybqaadashada tijaabada caafimaadka. La hadal dhakhtarkaaga si uu kaaga caawiyo go aansashada haddii mid kugu habboon yahay.

Tijaabooyinka 1-25 ee 260 1 2 3 ... 11 Ku xiga>

Daaweynta Bartilmaameedka ah ee Lagu Hagayo Tijaabinta Hidaha ee Lagu Daaweynayo Bukaannada leh Burooyinka Adag ee Soo Noqda, Lymphomas, ama Multiye Myeloma (Tijaabada Baaritaanka MATCH)

Marxaladan tijaabada ah ee 'MATCH' waxay daraasad ku sameysaa sida ugu wanaagsan ee daaweynta ee ay hogaamiso baaritaanka hidda-socodka ay ugu shaqeyso bukaanada qaba burooyinka adag ama lymphomas-ka ee horumar sameeyay ka dib ugu yaraan hal xariiq oo ah daaweynta caadiga ah ama aan lagu heshiin habka daaweynta. Tijaabooyinka hiddo-wadaha ayaa fiiriya maaddada hiddo-wadaha (hiddo-wadaha) gaarka ah ee unugyada burooyinka bukaannada. Bukaannada qaba cilladaha hidde-ahaaneed (sida is-beddelka, kordhinta, ama beddelidda) ayaa laga yaabaa inay ka faa'iideystaan ​​wax badan oo ka mid ah daaweynta oo bartilmaameedsanaya cilladaha hiddo-wadaha gaarka ah ee burooyinka. Aqoonsiga cilladahan hidde-ahaaneed marka hore waxay ka caawin kartaa dhakhaatiirta inay qorsheeyaan daaweyn wanaagsan oo loogu talagalay bukaannada qaba burooyinka adag, lymphomas, ama myeloma badan.

Goobta: 1189 goobood

Pembrolizumab ee Daaweynta Bukaannada Heerka III-IV Melanoma Khatarta Sare Melanoma Qalliinka Kahor iyo Kadib

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida pembrolizumab uu u shaqeeyo kahor iyo kadib qalliinka si loogu daaweeyo bukaanada qaba heerka melanoma ee heerka III-IV Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Siinta pembrolizumab qalliinka ka hor iyo ka dib ayaa si fiican uga shaqeyn kara daaweynta melanoma.

Goobta: 709 goobood

Dabrafenib iyo Trametinib Waxaa raacay Ipilimumab iyo Nivolumab ama Ipilimumab iyo Nivolumab Waxaa raacaya Dabrafenib iyo Trametinib oo lagu daaweynayo bukaanada heerka 3-IV BRAFV600 Melanoma

Marxaladan tijaabada ah ee wajiga III ah ayaa la darsayaa sida ugu wanaagsan ee daaweynta bilowga ah ee ipilimumab iyo nivolumab oo ay ku xigto dabrafenib iyo trametinib ay u shaqeyso waxayna la barbardhigeysaa daaweynta bilowga ah ee dabrafenib iyo trametinib oo ay ku xigto ipilimumab iyo nivolumab oo lagu daaweynayo bukaanada qaba heerka III-IV melanoma oo ay kujirto isbeddel loo yaqaan BRAFV600 lagumana saari karo qalliin (lama aqbali karo). Immunotherapy oo leh unugyada unugyada monoclonal, sida ipilimumab iyo nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Dabrafenib iyo trametinib waxay xannibayaan koritaanka burooyinka iyagoo bartilmaameedsanaya hidda-wadaha BRAFV600.

Goobta: 712 goobood

Ipilimumab oo leh ama aan lahayn Nivolumab ee lagu daaweynayo bukaanada qaba Melanoma Taasi oo ah Marxaladda IV ama Marxaladda III lagamana saari karo qalliin

Tijaabadan wejiga II ah waxay darsaysaa sida ugu wanaagsan ee ipilimumab leh ama aan lahayn nivolumab ay ugu shaqeyso daaweynta bukaanada qaba melanoma oo ah heerka IV ama heerka III lagana saari karin qalliin Immunotherapy oo leh unugyada unugyada monoclonal, sida ipilimumab iyo nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 600 oo goobood

Pembrolizumab ee lagu daaweynayo bukaanka qaba Melanoma-da 'Desmoplastic Melanoma' ama aan lagu saari karin qalliin

Tijaabadan tijaabada wajiga labaad ah waxay daraaseyneysaa sida wanaagsan ee pembrolizumab ugu shaqeeyo daaweynta bukaanada qaba melanoma-da (desmoplastic melanoma (DM) oo qalliin looga saari karo ama looga saari karin). Unugyada Monoclonal, sida pembrolizumab, waxay xannibayaan borotiinno gaar ah oo xoojin kara nidaamka difaaca jirka iyo xakameynta koritaanka burooyinka.

Goobta: 202 goobood

Daraasadda Basket-ka ee 'Entrectinib' (RXDX-101) ee loogu talagalay Daaweynta Bukaannada leh Dhuxul Adag oo Xambaarsan NTRK 1/2/3 (Trk A / B / C), ROS1, ama ALK Gene Rearrangements (Fusions)

Kani waa sumad furan, multicenter, daraasad balaaran oo caalami ah Wajiga 2 dambiisha ee entrectinib (RXDX-101) ee daaweynta bukaanada leh burooyinka adag ee xambaarsan NTRK1 / 2/3, ROS1, ama isugeynta hiddo wadaha ALK. Bukaannada waxaa loo qoondeyn doonaa dambiilo kala duwan iyadoo loo eegayo nooca burooyinka iyo isku-darka hidda-wadaha.

Goobta: 26 goobood

Badbaadada iyo waxtarka Pembrolizumab Marka loo barbardhigo placebo ee Daraasada Heerka Sare ee Cilmi-baarista II Melanoma (MK-3475-716 / KEYNOTE-716)

Daraasaddan 2-qayb ah waxay qiimeyn doontaa amniga iyo waxtarka pembrolizumab (MK-3475) marka la barbardhigo placebo ee kaqeybgalayaasha qalliinka loogu sameeyay qalliinka sare ee qalliinka sare ee melanoma. Kaqeybgalayaasha Qeybta 1 waxay kuheli doonaan pembrolizumab ama placebo qaab laba-indho-indheyn ah illaa iyo wareegyada 17. Ka-qaybgalayaasha qaata placebo ama joojiya daaweynta ka dib markay helaan 17 wareegyada pembrolizumab ee Qaybta 1, ma la kulmaan cudur soo noqnoqda 6 bilood gudahood markay dhammaystiraan pembrolizumab Qaybta 1, mana joojiso daaweynta pembrolizumab ee soo noqoshada cudurka ama dulqaad la'aanta, waxay xaq u yeelan hel ilaa 35 wareeg oo dheeri ah oo ah pembrolizumab Qaybta 2 qaab naqshad furan. Qiyaasta asaasiga ah ee daraasaddan ayaa ah in pembrolizumab ay kordhiso badbaado-soo-noqosho la'aan (RFS) marka la barbar dhigo placebo.

Goobta: 25 goobood

Nivolumab oo leh ama aan lahayn Ipilimumab ee Daaweynta Bukaanka Da'da Yar ee leh Burooyinka Soo noqnoqda ama Diidmada leh ama Sarcomas

Tijaabadan wajiga I / II waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca iyo qiyaasta ugu fiican ee nivolumab marka la siiyo ama aan lahayn ipilimumab si loo arko sida wanaagsan ee ay ugu shaqeeyaan daaweynta bukaanada yar yar ee leh burooyinka adag ama sarcomas soo laabtay (soo noqnoqda) ama aan ka jawaabin daaweynta diidmo) Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Weli lama oga in nivolumab uu kaligiis si fiican u shaqeeyo ama ipilimumab si loogu daaweeyo bukaanada qaba burooyinka adag ama soo noqnoqda ee diidan.

Goobta: 24 goobood

Daraasad Kordhinta Qiyaasta iyo Cohort Ballaarinta Daraasadda ee NKTR-214 ee Isku-darka Nivolumab iyo Daaweynta kale ee Ka-hortagga Kansarka ee Bukaannada leh Xulo Xannuunno Adag (PIVOT-02)

Daraasaddan afarta qaybood ah, NKTR-214 waxaa lagu maamuli doonaa iyadoo lagu darayo nivolumab Qaybta 1, iyadoo lagu darayo nivolumab oo leh ama aan lahayn noocyo kala duwan oo kiimiko ah Qaybta 2, iyo nivolumab iyo ipilimumab ee Qaybaha 3 & 4. Qaybta 1, Waxaa lagu talinayaa Wajiga 2 Qiyaasta (RP2D) ee NKTR-214 oo lagu daray nivolumab ayaa la go'aamin doonaa. Qeybta 2, NKTR-214 oo leh nivolumab oo ka tirsan RP2D ayaa lagu qiimeyn doonaa sida daaweynta safka hore iyo / ama daaweynta labaad ama seddexaad ee daaweynta bukaannada la xushay ee Melanoma, Renal Cell Carcinoma (RCC), Kansarka Sambabka ee Unugyada Yar Yar (NSCLC) ), Urothelial Carcinoma (UC), Kansarka Naasaha ee Naasaha (mBC) iyo Kansarka Qalitaanka (CRC). Intaa waxaa dheer, Qaybta 2, RP2D ee NKTR-214 oo leh nivolumab iyo noocyo kala duwan oo kiimiko ah iyo nidaamyo xulasho wadaag ah oo bukaannada NSCLC ah ayaa la go'aamin doonaa. Qeybta 3, dhowr nidaam oo kala duwan oo ka kooban isku-darka saddexda ah ee NKTR-214 oo lagu daray nivolumab iyo ipilimumab ayaa lagu qiimeyn doonaa bukaannada la xushay ee RCC, NSCLC, Melanoma, iyo UC. Qeybta 4, amniga iyo waxtarka isku dhafka seddex-geesoodka ayaa lagu sii qiimeyn doonaa dheeraad ah xulashada bukaanada leh RCC, NSCLC, Melanoma iyo UC.

Goobta: 22 goobood

Daraasada Wajiga 1 / 1b ee lagu Qiimaynayo Nabadgalyada iyo U dulqaadashada CPI-444 Kalidaa iyo Isku Darka Atezolizumab ee Kansarrada Horukacsan

Tani waa wajiga 1 / 1b-calaamadeynta furan, xarumo badan, daraasad xulashada qiyaasta ee CPI-444, oo ah maaddooyin yar oo afka laga qaato oo lagu beegsanayo soo-qaadaha adenosine-A2A ee T-lymphocytes iyo unugyada kale ee habka difaaca jirka. Tijaabadani waxay daraasad ku samayn doontaa nabadgelyada, dulqaadka, iyo waxqabadka ka hortagga burooyinka ee CPI-444 oo ah hal wakiil isla markaana lagu daro atezolizumab, PD-L1 inhibitor ka dhan ah burooyinka kala duwan ee adag. CPI-444 ayaa xannibaysa adenosine si loogu xidho daaweeyaha A2A. Adenosine wuxuu xakameynayaa waxqabadka anti-buro ee unugyada T iyo unugyada kale ee difaaca.

Goobta: 22 goobood

Daraasad ku saabsan Pembrolizumab (MK-3475) ee Kaqeybgalayaasha Caafimaadka Carruurta oo leh Tumor adag ama Lymphoma (MK-3475-051 / KEYNOTE-051)

Tani waa daraasad laba qaybood ah oo ku saabsan pembrolizumab (MK-3475) ee kaqeybgalayaasha cudurada carruurta ee leh nooc kasta oo ka mid ah kansarka soo socda: ligand 1 (PD-L1) - buro adag oo halis ah ama lymphoma kale (6 bilood illaa <18 sano jir), - dib u noqosho ama diidmo fasalka Hodgkin lymphoma (rrcHL) (3 sano ilaa <18 sano jir), ama soo-noqoshada ama diidmada microsatelite-xasilloonida-sare (MSI-H) burooyin adag (6 bilood illaa <18 sano jir). Qeybta 1 waxay heli doontaa qiyaasta ugu badan ee loo dulqaadan karo (MTD) / qiyaasta ugu badan ee la maamulo (MAD), waxay xaqiijinaysaa qiyaasta, waxayna heli doontaa qiyaasta Wajiga 2 ee lagu taliyay (RP2D) ee daaweynta pembrolizumab. Qaybta 2 waxay sii qiimeyn doontaa amniga iyo waxtarka carruurta ee RP2D. Qiyaasta asaasiga ah ee daraasaddan ayaa ah maamulka xididka (IV) ee pembrolizumab ee carruurta leh melanoma haysa; PD-L1 oo ah mid horumarsan, soo noqnoqday ama buro adag oo diidan ama lymphoma kale; buro adag oo MSI-H ah oo dib-u-soo-noqosho leh ama dib-u-dhac ah; ama rrcHL, waxay keeni doontaa Heerka Jawaabta Ujeeddada (ORR) oo ka badan 10% ugu yaraan mid ka mid ah noocyada kansarka. Isbedelka 8, diiwaangelinta kaqeybgalayaasha leh burooyinka adag iyo kaqeybgalayaasha da'doodu tahay 6 bilood illaa <12 sano ee melanoma ayaa la xiray. Diiwaangelinta kaqeybgalayaasha da'doodu udhaxeyso ≥12 sano ilaa ≤18 sano ee melanoma ayaa socota. Diiwaangelinta kaqeybgalayaasha leh burooyinka adag ee MSI-H sidoo kale way sii socdaan. buro adag oo MSI-H ah oo soo noqnoqotay ama diidmo ah; ama rrcHL, waxay keeni doontaa Heerka Jawaabta Ujeeddada (ORR) oo ka badan 10% ugu yaraan mid ka mid ah noocyada kansarka. Isbedelka 8, diiwaangelinta kaqeybgalayaasha leh burooyinka adag iyo kaqeybgalayaasha da'doodu tahay 6 bilood illaa <12 sano ee melanoma ayaa la xiray. Diiwaangelinta kaqeybgalayaasha da'doodu udhaxeyso ≥12 sano ilaa ≤18 sano ee melanoma ayaa socota. Diiwaangelinta kaqeybgalayaasha leh burooyinka adag ee MSI-H sidoo kale way sii socotaa. buro adag oo MSI-H ah oo soo noqnoqotay ama diidmo ah; ama rrcHL, waxay keeni doontaa Heerka Jawaabta Ujeeddada (ORR) oo ka badan 10% ugu yaraan mid ka mid ah noocyada kansarka. Isbedelka 8, diiwaangelinta kaqeybgalayaasha leh burooyinka adag iyo kaqeybgalayaasha da'doodu tahay 6 bilood illaa <12 sano ee melanoma ayaa la xiray. Diiwaangelinta kaqeybgalayaasha da'doodu udhaxeyso ≥12 sano ilaa ≤18 sano ee melanoma ayaa socota. Diiwaangelinta kaqeybgalayaasha leh burooyinka adag ee MSI-H sidoo kale way sii socotaa.

Goobta: 19 goobood

Badbaadada iyo Waxtarka ee IMCgp100 oo kahortaga Xulashada Baarayaasha ee Advanced Uveal Melanoma

Si loo qiimeeyo badbaadada guud ee HLA-A * 0201 bukaanada qaangaarka ah ee qaangaarka ah ee aan horay loo daaweyn UM ee qaata IMCgp100 marka la barbar dhigo Xulashada Baaraha dacarbazine, ipilimumab, ama pembrolizumab.

Goobta: 18 goobood

Enapotamab Vedotin (HuMax-AXL-ADC) Daraasada Badbaadada ee Bukaannada leh Burooyinka Adag

Ujeedada tijaabada ayaa ah in la ogaado qiyaasta ugu badan ee loo dulqaadan karo iyo in la dhiso astaanta badbaadada ee HuMax-AXL-ADC ee dad isku dhafan oo bukaanno leh burooyin adag oo cayiman.

Goobta: 18 goobood

Daraasad ku saabsan XmAb®20717 oo ku saabsan Mawduucyo leh Burooyin Adag oo Xul ah

Tani waa Wajiga 1, qaadasho badan, daraasad kordhinta qiyaasta kor u qaadista si loo qeexo MTD / RD iyo nidaamka XmAb20717, si loo sharaxo nabadgelyada iyo dulqaadka, si loo qiimeeyo PK iyo difaaca jirka, iyo in si hordhac ah loo qiimeeyo dhaqdhaqaaqa ka hortagga burooyinka ee XmAb20717 maadooyinka leh xulashada burooyinka adag ee horumarsan.

Goobta: 15 goobood

Talimogene Laherparepvec iyo Pembrolizumab ee Daaweynta Bukaannada Heerka III-IV Melanoma

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee talimogene laherparepvec iyo pembrolizumab uga shaqeeyaan daaweynta bukaanka qaba heerka III-IV melanoma. Daaweynta nafleyda, sida talimogene laherparepvec, waxay isticmaalaan walxaha laga sameeyay noolaha noolaha oo kicin kara ama cabudhin kara habka difaaca jirka siyaabo kala duwan una joojin kara unugyada burooyinka inay soo baxaan Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Siinta talimogene laherparepvec iyo pembrolizumab ayaa si fiican uga shaqeyn kara daaweynta bukaanada qaba melanoma iyaga oo yareeya burada.

Goobta: 16 goobood

Dabrafenib, Trametinib, iyo Navitoclax ee lagu daaweynayo bukaanada qaba BRAF Mutant Melanoma ama Burooyinka Adag ee Metastatic ah ama aan lagu saari karin qalliin

Tijaabadan wajiga koowaad ee I / II waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca iyo sida ugu fiican ee loo isticmaali karo dabrafenib, trametinib, iyo navitoclax iyo in la arko sida wanaagsan ee ay ugu shaqeeyaan daaweynta bukaanada qaba cudurka BRAF melanoma mutant ama burooyin adag oo ku faafay qaybaha kale ee jirka ama aan laga saari karin. qalliin. Dabrafenib, trametinib, iyo navitoclax ayaa laga yaabaa inay joojiyaan koritaanka unugyada burooyinka iyagoo xannibaya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada.

Goobta: 24 goobood

Daraasad ku saabsan Avelumab oo isku dhafan oo leh Immunotherapies kale oo Kansar ah oo ku jira Xanuunada Hormarsan (JAVELIN Medley)

Tani waa wajiga 1b / 2 qaadasho-daraasad-daraasad si loo qiimeeyo amniga, farmasokokinikada, farmashiyeyaasha, iyo waxqabadka antitumor hordhaca ah ee avelumab (MSB0010718C) oo ay weheliso daawooyinka kale ee daaweynta kansarka ee bukaanka qaba burooyinka adag ee maxalliga ah ama metastatic. Ujeedada ugu weyn ayaa ah in la qiimeeyo badbaadada iyo calaamadaha hore ee waxtarka ee isku dhafka avelumab ee kala duwan ee ka hortagga kansarka, iyadoo la hagaajinayo qiyaasta daawada sida ugu habboon, tilmaamo taxane ah oo kooban.

Goobta: 12 goobood

Daraasad Immuno-therapy ah oo baaris ah oo lagu qiimeynayo amniga, dulqaadka iyo wax ku oolnimada anti-LAG-3 Iyadoo iyo aan laheyn anti-PD-1 ee Daaweynta Burooyinka Adag

Ujeedada daraasaddan ayaa ah in la qiimeeyo amniga, dulqaadka iyo waxtarka daawada tijaabada ah ee BMS-986016 oo kaligeed la bixiyo isla markaana lagu daro nivolumab bukaanada qaba burooyinka adag ee faafay iyo / ama aan lagu saari karin qalliin. Noocyada burooyinka ee soosocda waxay kujiraan daraasadan: Kansarka Sambabka Unugyada Yar Yar (NSCLC), kansarka caloosha, kansarka qanjirka 'hepatocellular carcinoma', kansarka kilyaha ee kelyaha, kansarka kaadiheysta, kansarka unugyada unugyada ee madaxa iyo qoorta, iyo melanoma, oo aan horey u dhicin lagu daweeyey tallaal. NSCLC iyo melanoma oo horey loogu daweeyey immunotherapy.

Goobta: 12 goobood

Badbaadada, U dulqaadashada iyo Daraasadda PK ee DCC-2618 ee Bukaannada leh Astaamaha Xun

Tani waa Wejiga 1, calaamadda furan, daraasadda sare-u-kicinta-bini-aadamka (FIH) ee qiyaasta-kordhinta loogu talagalay in lagu qiimeeyo amniga, dulqaadka, farmasokokinetics (PK), farmashiyeyaasha firfircoonida (PD) iyo waxqabadka hordhaca ah ee ka hortagga DCC-2618, oo lagu maamulo afka (PO), bukaanka qaangaarka ah ee leh astaamaha horumarsan. Daraasadu waxay ka kooban tahay 2 qaybood, waji-kordhin heer iyo waji-ballaarin.

Goobta: 12 goobood

Daraasad ku saabsan NKTR-214 oo lagu daray Nivolumab vs Nivolumab Kalidaa kaqeybgalayaasha leh Melanoma aan horey loo daaweyn karin ama Melanoma

Ujeedada daraasadda ayaa ah in la tijaabiyo waxtarka (sida ugu wanaagsan ee daroogadu u shaqeyso), badbaadada, iyo dulqaadka daroogada baaritaanka ee loo yaqaan NKTR-214, marka lagu daro nivolumab iyo nivolumab oo kali laga siiyo kaqeybgalayaasha horay aan loo daweyn kansarka maqaarka melanoma oo ah aan qalliin looga saari karin ama ku faafin

Goobta: 10 goobood

Daraasad ku saabsan Relatlimab Plus Nivolumab iyo Nivolumab Kalidaa kaqeybgalayaasha leh Melanoma Advanced

Ujeedada daraasaddan ayaa ah in la go'aamiyo in nivolumab oo ay weheliso relatlimab ay ka waxtar badan tahay nivolumab kaligeed iyada oo lagu daaweynayo melanoma ama melanoma oo aan la faafin karin

Goobta: 13 goobood

Pembrolizumab iyo Ipilimumab ee Daaweynta Bukaanka ee Melanoma horey loogu daweeyey

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee pembrolizumab iyo ipilimumab uga shaqeeyaan daaweynta bukaanada qaba melanoma hore loo daweeyey oo ku faafay qaybaha kale ee jirka. Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab iyo ipilimumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 10 goobood

Daraasada Caafimaadka ee CMP-001 ee Isku-dhafka Pembrolizumab ama sida daaweynta monotherapy

Daraasaddan waxaa lagu samayn doonaa laba qaybood: Qaybta 1 waxaa lagu qaban doonaa iyadoo la isticmaalayo Qiyaasta Qiyaasta iyo Balaadhinta Naqshadeynta. Wejiga Ka-fogaanshaha Qiyaasta Qeybta 1 ee daraasaddan ayaa tilmaami doonta qiyaas badbaado leh oo loo dulqaadan karo oo lagu sii qiimeyn doono qeybta Ballaarinta Qiyaasta Qeybta 1. Qaybta 2 ee daraasadda waxaa lagu samayn doonaa si is barbar socota Qaybta 1 Qiyaasta Ballaarinta Qiyaasta waxayna qiimeyn doontaa nabadgelyada iyo waxtarka CMP-001 markii loo isticmaalo monotherapy.

Goobta: 12 goobood

Wejiga 1b / 2 Tijaabada Lenvatinib (E7080) iyo Plus Pembrolizumab ee Mawduucyada leh Burooyinka adag ee Xullan

Tani waa calaamad furan oo ah wajiga 1b / 2 tijaabada lenvatinib (E7080) iyo pembrolizumab ee kaqeybgalayaasha leh burooyin adag oo la xushay. Marxaladda 1b ayaa go'aamin doonta oo xaqiijin doonta qiyaasta ugu dulqaadashada badan (MTD) ee lenvatinib oo ay weheliso 200 milligram (mg) (xididdada [IV], toddobaad kasta 3 [Q3W]) pembrolizumab ee kaqeybgalayaasha leh burooyin adag oo la xushay (ie, sambabka unugyada aan yareyn) kansarka, kansarka kelyaha, endometrial carcinoma, urothelial carcinoma, kansarka unugyada kansarka ee madaxa iyo qoorta, ama melanoma). Wejiga 2 (Ballaarinta) wuxuu qiimeyn doonaa nabadgelyada iyo waxtarka isku dhafka 6 wada-hawlgalayaasha MTD laga bilaabo Wajiga 1b (lenvatinib 20 mg / maalin afka ah + pembrolizumab 200 mg Q3W, IV).

Goobta: 10 goobood

Daraasada Lifileucel (LN-144), Tumor Autologous Lymphocytes, ee Daaweynta Bukaannada qaba Melanoma Metastatic

Mustaqbalka, daraasad fara badan oo fara-gelin ah oo lagu qiimeynayo daaweynta unugyada korsashada (ACT) iyada oo la adeegsanayo faleebada LN-144 (autologous TIL) oo ay ku xigto interleukin 2 (IL-2) ka dib nidaam aan shuruud lahayn oo loo yaqaan 'NMA LD'.

Goobta: 13 goobood

1 2 3 ... 11 Xiga>